natgillin/translations-raw huggingface dataset:
passing urine more often enlarged breasts in men
pogostejše odvajanje urina, povečanje prsi pri moških.
passing urine more often enlarged breasts in men.
pogostejše odvajanje urina, povečanje prsi pri moških.
passing water (urinating) less frequently than normal
manj pogosto odvajanje vode (uriniranje) kot običajno
Passing wind
vetrovi
Passing wind (flatulence), haemorrhoids, ulcer, cavities
vetrovi (flatulenca), hemoroidi, razjede, kavitete;
passing wind, difficulty passing stools
vetrovi, težave pri odvajanju blata
Passive immunisation of piglets from vaccinated gilts and sows to reduce mortality and clinical signs of Aujeszky’s disease and to reduce the excretion of Aujeszky’s disease field virus.
Pasivna imunizacija pujskov, katerih matere so bile cepljene, z namenom zmanjšanja pogina in manifestacije kliničnih znakov zaradi Aujeszkyjeve bolezni in za zmanjšanje prisotnosti virusa v okolju.
Passive immunisation of the progeny of vaccinated gilts and sows to reduce mortality and clinical signs of Aujeszky’s disease and to reduce the excretion of Aujeszky’s disease field virus.
Pasivna imunizacija pujskov, katerih matere so bile cepljene, z namenom zmanjšanja pogina in manifestacije kliničnih znakov zaradi Aujeszkyjeve bolezni in za zmanjšanje prisotnosti virusa v okolju.
Passive transmission of antibodies to erythrocyte antigens, e.g.
Pasiven prenos protiteles proti antigenom eritrocitov (npr.
Passive transmission of antibodies to erythrocyte antigens, e.g.
Pasivni prenos protiteles na eritrocitne antigene, npr.
Passive transmission of antibodies to erythrocyte antigens, e.g.
Pasivno prenašanje protiteles proti antigenom eritrocitov, npr.
Passive transmission of antibodies to erythrocyte antigens, e.g.
Pasivno prenašanje protiteles proti antigenom eritrocitov,npr.
past experience with excessive gambling severe liver problems.
če ste kdaj imeli težave s pretiranim hazardiranjem, hude težave z jetri.
patch
obliž
patch of 28 cm2 contains 8.4 mg of testosterone and provides 300 micrograms per 24 hours.
obliž s površino 28 cm2 vsebuje 8,4 mg testosterona in sprosti 300 mikrogramov testosterona v 24 urah.
Patches must always be applied regularly, on the same day of the week.
Obliže je treba redno nameščati na isti dan v tednu.
patches of darkened skin
temne lise na koži
patchy bleeding in the skin
krvavenje kože v obliki zaplat
Patency data from the phase I and II angiographic studies suggest that tenecteplase, administered as a single intravenous bolus, is effective in dissolving blood clots in the infarct-related artery of subjects experiencing an AMI on a dose related basis.
Podatki o prehodnosti iz angiografskih raziskav I. in II. faze kažejo, da tenekteplaza v enkratnem intravenskem bolusu pri bolnikih z akutnim miokardnim infarktom učinkovito in od velikosti odmerka odvisno raztaplja krvne strdke v arteriji, ki jo je prizadel infarkt.
Patent ductus arteriosus is a condition where the ductus arteriosus (the blood vessel that allows blood to bypass the baby’s lungs before birth) fails to close after birth.
Pri odprtem arterioznem duktusu gre za stanje, ko se arteriozni duktus (žila, ki pred rojstvom omogoča, da kri zaobide otrokova pljuča) po rojstvu ne zapre.
Pathogen
Bakterija
pathogen(s) and the
patogena/patogenov in
Pathogens of the family Proteeae (Proteus spp., Providencia spp., and Morganella spp.) are generally less susceptible to tigecycline than other members of the Enterobacteriaceae.
Patogeni družine Proteeae (Proteus spp., Providencia spp. in Morganella spp.) so na splošno manj občutljivi za tigeciklin kot druge Enterobacteriaceae.
Pathological gambling
Patološko hazardiranje
Pathological gambling Aggression
patološko hazardiranje agresija
Pathological gambling, increased libido, hypersexuality, , compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Pramipexole Accord. (see section 4.4).
Pri bolnikih, ki so se zdravili z dopaminskimi agonisti, tudi zdravilom Pramipeksol Accord, se lahko pojavijo patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno trošenje denarja ali nakupovanje, prenajedanje in kompulzivno uživanje hrane (glejte poglavje 4.4).
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Oprymea (see section 4.4).
Pri bolnikih, ki so se z dopaminskimi agonisti, tudi z zdravilom Oprymea, se lahko pojavijo patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno trošenje denarja ali nakupovanje, prenajedanje in kompulzivno uživanje hrane (glejte poglavje 4.4).
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Oprymea (see section 4.4).
Pri bolnikih, ki so se zdravili z dopaminskimi agonisti, tudi zdravilom Oprymea, se lahko pojavijo patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno trošenje denarja ali nakupovanje, prenajedanje in kompulzivno uživanje hrane (glejte poglavje 4.4).
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine (see section 4.4).
Pri bolnikih, zdravljenih z agonisti dopamina, vključno z rotigotinom, se lahko pojavi patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno zapravljanje ali nakupovanje, prenajedanje in kompulzivno prehranjevanje (glejte poglavje 4.4.
Pathomorphological injection site reactions (including reversible changes of congestion, oedema, fibrosis and haemorrhage) are present for approximately 30 days after injection.
Patomorfološke reakcije na mestu injiciranja (vključno z reverzibilnimi spremembami kongestije, edemom, fibrozo in krvavitvami) so prisotne približno 30 dni po injiciranju.
Pathomorphological injection site reactions (including reversible changes of congestion, oedema, fibrosis and haemorrhage) are very common for approximately 30 days after injection in cattle and pig.
Patomorfološke reakcije na mestu injiciranja (vključno z reverzibilnimi spremembami kongestije, edemom, fibrozo in krvavitvami) so zelo pogoste, še približno 30 dni po injiciranju pri govedu in prašičih.
Pathomorphological injection site reactions (including reversible changes of congestion, oedema, fibrosis and haemorrhage) are very common for approximately 30 days after injection in cattle and pigs.
Reakcije na mestu vbrizgavanja lahko zaznamo patomorfološko so zelo pogoste 30 dni po vbrizgovanju zdravila pri govedu in prašičih.
pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated.
Znano je, da sildenafil učinkuje na pot dušikov oksid/ciklični gvanozinmonofosfat (cGMP) (glejte poglavje 5.1) in tako okrepi hipotenzivno delovanje nitratov, zato je sočasno jemanje z donorji dušikovega oksida (npr. z amilnitritom) ali nitrati v kakršnikoli obliki kontraindicirano.
pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated.
Znano je, da sildenafil učinkuje na pot dušikov oksid/ciklični gvanozinmonofosfat (cGMP) (glejte poglavje 5.1), in tako okrepi hipotenzivno delovanje nitratov, zato je njegova sočasna uporaba z donorji dušikovega oksida (npr. amilnitritom) ali nitrati v kakršni koli obliki kontraindicirana.
pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated.
Znano je, da sildenafil učinkuje na pot dušikov oksid/ciklični gvanozinmonofosfat (cGMP) (glejte poglavje 5.1), in tako okrepi hipotenzivno delovanje nitratov, zato je njegova sočasna uporaba z donorji dušikovega oksida (npr. amilnitritom) ali nitrati v kakršnikoli obliki kontraindicirana.
pathway e.g. budesonide.
indromom in adrenalno
Patie nts with high blood pre ssure
Bolniki z visokim krvnim tlakom
Patient
podskupina bolnic
Patient / caregivers educational material
Izobraževalno gradivo za bolnike / negovalce
Patient alert card
Bolnikova kontrolna izkaznica
PATIENT ALERT CARD
KONTROLNA KARTICA ZA BOLNIKA
Patient Alert Card
Opozorilna kartico za bolnika
Patient alert card
Opozorilno kartico bolnika
Patient alert card
Opozorilno kartico za bolnika
Patient Alert Card (to be given to the patient): to remind patients, physicians and/or pharmacists of the important safety information related to the use of Xyrem.
Opozorilna kartica za bolnike (prejme bolnik): bolnike, zdravnike in/ali farmacevte opomni glede pomembnih varnostnih informacij v povezavi z uporabo zdravila Xyrem.
Patient Alert Card for Phototoxicity and SCC:
Opozorilna izkaznica za bolnika za fototoksičnost in ploščatocelični karcinom:
Patient Alert Card for Phototoxicity and SCC:
Opozorilna kartica za bolnika za fototoksičnost in ploščatocelični karcinom:
Patient alert card inside.
Priložena je kontrolna kartica za bolnika.
Patient Alert Card specifically aimed at facilitating patients’ awareness of the need for regular blood tests for liver function.
Opozorilna kartica za bolnika, ciljno usmerjena k ozaveščanju bolnika o potrebi rednih krvnih preiskav zaradi preverjanja delovanja jeter.
Patient Alert Card specifically aimed at informing patients of the need to avoid pregnancy and to ensure effective contraceptive measures are used.
Opozorilna kartica za bolnika, ciljno usmerjena k obveščanju bolnikov o potrebi preprečitve zanositve in o zagotavljanju uporabe zanesljivih načinov kontracepcije.
PATIENT ALERT CARD TEXT FOR NON-ONCOLOGY INDICATIONS
BESEDILO OPOZORILNE IZKAZNICE BOLNIKA Z NEONKOLOŠKO INDIKACIJO
Patient Alert Card: For the patient to present to other healthcare providers to alert them to the use of LEMTRADA in this patient
Opozorilna kartica bolnika: ki jo bolnik pokaže drugim zdravstvenim delavcem, da jih opozori, da se zdravi z zdravilom LEMTRADA
Patient Alert Cards
Kontrolno kartico za bolnika
Patient Alert Cards (text as agreed by the CHMP)
Opozorilno kartico za bolnika (besedilo usklajeno s CHMP).
Patient Alert Cards [Text included in Annex III]
navodilo za predpisovanje in opozorilno kartico za bolnika (besedilo je vključeno v Dodatek III)
Patient assessment of constipation symptoms (PAC-SYM) questionnaire
Vprašalnik PAC-SYM (bolnikova ocena simptomov zaprtosti)
Patient Body Weight
Bolnikova telesna masa
Patient booklets
Izobraževalne brošure za bolnike
Patient cards
Kartice za bolnike
Patient cards and/or equivalent tools:
Kartice za bolnike in/ali ustrezno orodje:
Patient cards to be given to patients with the product
Opozorilno kartico za bolnike, ki jo bolnik prejme skupaj z zdravilom
Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving ISENTRESS 400 mg twice daily and the group receiving efavirenz 600 mg at bedtime.
Demografske (spol, starost in rasa) in izhodiščne značilnosti bolnikov so bile med skupino, ki je prejemala zdravilo ISENTRESS v odmerku 400 mg dvakrat na dan, in skupino, ki je prejemala efavirenz v odmerku 600 mg pred spanjem, primerljive.
Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving raltegravir 400 mg twice daily and the group receiving efavirenz 600 mg at bedtime.
Demografske (spol, starost in rasa) in izhodiščne značilnosti bolnikov so bile med skupino, ki je prejemala 400 mg raltegravirja dvakrat na dan, in skupino, ki je prejemala 600 mg efavirenza pred spanjem, primerljive.
Patient demographics (gender, age and race) and baseline characteristics were comparable between the groups receiving ISENTRESS 400 mg twice daily and placebo.
Pri bolnikih v skupini, ki je prejemala zdravilo ISENTRESS v odmerku 400 mg dvakrat na dan, in bolnikih v skupini, ki je prejemala placebo, so bile demografske značilnosti (spol, starost in rasa) ter izhodiščne značilnosti primerljive.
Patient details, signature and date
podatke bolnika, podpis in datum
Patient details, signature and date
podatki o bolniku, podpis in datum
patient develops symptoms or signs of potential liver injury (such as dark urine, light coloured stools, yellow skin/eyes, pain in the upper right belly, sustained new-onset and unexplained fatigue). the increase in serum transaminases exceeds 3 X upper limit of normal.
če se pri bolniku pojavijo simptomi ali znaki možne poškodbe jeter (kot je temen urin, svetlo obarvano blato, rumena koža/oči, bolečine v zgornjem desnem delu trebuha, nastop dolgotrajne in nepojasnjene utrujenosti); če zvišanje aminotransferaz v serumu presega 3-kratno zgornjo mejo normalnih vrednosti.
Patient disposition
Dispozicija bolnika
Patient disposition
Lastnosti bolnikov
Patient dose (mg) divided by 1 (mg/ml concentrate of Vimizim) = Total number of ml of Vimizim
Odmerek za bolnika (mg), deljen z 1 (mg/ml koncentrata zdravila Vimizim) = skupna količina zdravila Vimizim v ml
Patient educational material
Komplet podatkov o zdravilu za bolnika
Patient emergency information cards
Informacijsko izkaznico bolnika za nujne primere.
Patient evaluation and selection;
ocenjevanje in izbira bolnikov;
Patient frequencies are defined as: very common ≥1/10; common ≥1/100 to <1/10; uncommon ≥1/1,000 to
Pogostnosti pri bolnikih so opredeljene takole: zelo pogosti ≥ 1/10, pogosti ≥ 1/100 do < 1/10, občasni
Patient Global Assessment of Method of Pain Control -1st 24 hour (% of patients rating good or excellent)
Bolnikova celovita presoja metode lajšanja bolečine v prvih 24 urah (% presoj kot »dobra« ali »odlična«)
Patient group
Skupina bolnikov
Patient guide
Navodila za bolnike
Patient guide
Priročnik za bolnika
Patient guide
Vodnik za bolnike
Patient guide should contain the following key elements:
Priročnik za bolnika mora vsebovati naslednje ključne vsebine:
Patient Guide: For further information on autoimmune reactions, infections and other information.
Vodnik za bolnike: z dodatnimi informacijami o avtoimunskih reakcijah in okužbah ter drugimi informacijami.
Patient Incidence of Febrile Neutropenia
Incidenca bolnikov s febrilno nevtropenijo
Patient Incidence of Total Parenteral Nutrition (TPN)
Incidenca bolnikov s popolno parenteralno prehrano (PPP)
Patient incidence of WHO Grade 3/4 oral mucositis
Incidenca bolnikov z oralnim mukozitisom 3./4. stopnje po SZO
Patient incidence of WHO Grade 4 oral mucositis
Incidenca bolnikov z oralnim mukozitisom 4. stopnje
Patient information
Informacije za bolnika
Patient information
Informacije za bolnike
Patient Information
Podatki o bolniku ali bolnici
Patient information leaflet
navodila za uporabo;
Patient Information Leaflet
Navodilo za uporabo
Patient information leaflet
navodilo za uporabo zdravila za bolnika,
Patient information leaflet
Navodilo za uporabo.
Patient information pack
Informativni komplet za bolnika
Patient information pack
Komplet informacij za bolnike
Patient information pack
Komplet podatkov o zdravilu za bolnika
Patient information pack
Komplet podatkov o zdravilu za bolnika.
Patient information pack
Paket informacij za bolnike
Patient information pack
Vodnik za bolnika
Patient monitoring after intravitreal injection
premljanje bolnikov po intravitrealni injekciji
Patient monitoring after IVT injection
premljanje bolnika po intravitrealnem injiciranju
Patient monitoring after IVT injection
premljanje bolnika po intravitrealnem injiciranju,
Patient number (Pt N°) {patient number} Patient initials (Pt initials) {patient initials}
Številka bolnika (št. bolnika) {številka bolnika} Začetnice bolnika (začet. bolnika) {začetnice bolnika}
Patient numbers were n=72 for placebo, n=70 for vedolizumab every eight weeks, and n=73 for vedolizumab every four weeks
Število bolnikov: n=72 za placebo, n=70 za vedolizumab na vsakih osem tednov in n=73 za vedolizumab na vsake štiri tedne.
Patient numbers were n=82 for placebo, n=82 for vedolizumab every eight weeks, and n=80 for vedolizumab every four weeks
Število bolnikov: n=82 za placebo, n=82 za vedolizumab na vsakih osem tednov in n=80 za vedolizumab na vsake štiri tedne.
Patient population (N)
Populacija bolnikov (N)
Patient population IMP24011
Populacija bolnikov IMP24011
Patient population*
Populacija bolnikov
Patient populationa
Populacija bolnikova
Patient quick guides on the main programming functions
Hitri vodnik za bolnika o glavnih programskih funkcijah
Patient Reference:
Številka bolnika:
Patient reminder card
Opomnilno kartico za bolnika
Patient reminder card
Opozorilno kartico za bolnika
Patient reminder card on osteonecrosis of the jaw
Opozorilno kartico za bolnika z opozorili glede osteonekroze čeljusti.
Patient reminder cards
opozorilne kartončke za bolnika
Patient reported craving, withdrawal and reinforcing effects of smoking
Bolniki so navajali hlepenje, odtegnitvene učinke in okrepitvene učinke kajenja
Patient selection
izbiro bolnikov
Patient selection criteria
Merila za izbiro bolnikov.
Patient selection criteria including that Pioglitazone should not be used as first line therapy and emphasising the need for regular review of treatment benefit.
Merila za izbiro bolnika, ki vključujejo, da se pioglitazona ne sme uporabljati kot zdravilo prvega izbora in poudarijo potrebo po redni oceni koristi zdravljenja.
Patient selection criteria including that Pioglitazone should not be used as first line therapy and emphasising the need for regular review of treatment benefit.
Merilom za izbiro bolnikov; vključeno mora biti dejstvo, da se pioglitazona ne sme predpisovati kot zdravila prve izbire, in poudarjena mora biti potreba po rednem ocenjevanju koristi zdravljenja.
Patient selection criteria including that Pioglitazone should not be used as first line therapy and emphasising the need for regular review of treatment benefit.
Vključeno mora biti dejstvo, da se pioglitazona ne sme predpisovati kot zdravila prve izbire in poudarjena potreba po rednem ocenjevanju koristi zdravljenja.
Patient serum transaminase levels should be monitored monthly during treatment and up to 4 months after the last dose of Zinbryta.
Bolnikove ravni serumskih transaminaz je treba spremljati mesečno ves čas zdravljenja in še do 4 mesece po zadnjem odmerku zdravila Zinbryta.
Patient specific product not to be administered to other patients
Zdravila, specifičnega za bolnika, se ne sme dati drugim bolnikom.
Patient subpopulations - MabThera combination therapy
Podskupine bolnikov – kombinirano zdravljenje z zdravilom MabThera
Patient subpopulations - MabThera monotherapy
Podskupine bolnikov – samostojno zdravljenje z zdravilom MabThera
Patient subset
Starostna kategorija 1
Patient to drink urea solution, then fill bottle to line again and drink.
Bolnik zaužije raztopino sečnine, nato napolne stekleničko znova do oznake ter popije vsebino.
Patient Weight
Bolnikova telesna masa
Patient Weight
telesna masa bolnika
Patient weight (kg)
telesna masa bolnika (kg)
Patient weight (kg) multiplied by 2 (mg/kg) = Patient dose (mg)
Bolnikova telesna masa (kg), pomnožena z vrednostjo 2 (mg/kg) = odmerek za bolnika (mg)
Patient with the following conditions must not take MULTAQ:
Zdravila MULTAQ ne smejo jemati bolniki z naslednjimi stanji:
Patient ‘weight for age’ and ‘height for age’ percentiles of the normative population decreased during treatment.
Med zdravljenjem so se bolnikovi percentili telesne mase in višine bolnikov glede na normativno populacijo zmanjšali.
Patient- reported convenience and overall treatment satisfaction (as collected through a patient-reported outcomes questionnaire) were consistently higher with TOBI Podhaler compared with tobramycin nebuliser solution in each cycle.
Bolniki so dosledno pri vsakem ciklusu poročali o večji prikladnosti zdravljenja in izražali večje splošno zadovoljstvo z zdravljenjem (kar so ugotavljali s pomočjo vprašalnika o izidih zdravljenja, na katerega so odgovarjali bolniki) pri uporabi zdravila TOBI Podhaler v primerjavi z uporabo raztopine tobramicina za nebulator.
Patient-Reported Outcome - Gastrointestinal Symptoms Rating Scale
Izid po poročanju bolnikov – lestvica za oceno gastrointestinalnih simptomov
Patient-reported Outcomes
Izidi po navedbi bolnika
Patient-years of exposure
bolnikov-let izpostavljenosti
PATIENT/CARER REMINDER CARD
OPOZORILNA KARTICA ZA BOLNIKA/SKRBNIKA
Patient: (name - date of birth {DD.Mmm.YYYY}) Biopsy: {biopsy number}
Bolnik: (ime – datum rojstva {DD mmm LLLL}) Biopsija št.: {številka biopsije}
Patients
Bolnike, ki prejemajo
patients
bolnikov
Patients (%) achieving HbA1c
Bolniki (%), ki so dosegli HbA1c
Patients (%) achieving HbA1c < 7 %
Bolniki (%), ki so dosegli HbA1c ≤ 7
Patients (%) achieving HbA1c < 7%
bolniki (%), ki so dosegli HbA1c < 7
Patients (%) Achieving HbA1c <7%
Bolniki (%), ki so dosegli HbA1c < 7
Patients (%) achieving HbA1c <7%
Bolniki (%), ki so dosegli vrednost HbA1c < 7
Patients (%) achieving HbA1c <7%
Delež bolnikov (%), ki so dosegli vrednost HbA1c < 7
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7% at week 52b, 2
Bolniki (%) z izhodiščno vrednostjo HbA1c ≥ 7 %, ki so dosegli vrednost HbA1c < 7 % v
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%2
Bolniki (%) z izhodiščno vrednostjo HbA1c ≥ 7 %, ki so dosegli vrednost HbA1c
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%2
Bolniki (%) z izhodiščno vrednostjo HbA1c ≥ 7 %, ki so dosegli vrednost HbA1c < 7 %2
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%2
Bolniki (%), ki so dosegli vrednost HbA1c < 7 % z izhodiščno vrednostjo HbA1c ≥ 7 %2
Patients (%) achieving HbA1c <7.0%
Bolniki (%), ki so dosegli HbA1c < 7,0
Patients (%) achieving HbA1c ≤ 7 %
Bolniki (%), ki so dosegli HbA1c ≤ 7
Patients (%) achieving HbA1c 6.5%
Bolniki (%), ki so dosegli vrednost HbA1c  6,5
Patients (%) achieving HbA1c 6.5%
Delež bolnikov (%), ki so dosegli vrednost HbA1c  6,5
Patients (%) achieving HbA1c<7%
Bolniki (%), ki so dosegli vrednost HbA1c< 7
Patients (%) receiving rescue treatment
Bolniki (%), ki so prejeli reševalno zdravilo
Patients (n = 199) were evaluated for anti-therapeutic antibody responses to daratumumab at multiple time points during treatment and up to 8 weeks following the end of treatment.
Pri bolnikih (n = 199) so večkrat med zdravljenjem in do 8 tednov po zaključku zdravljenja z daratumumabom preverjali prisotnost protiteles proti daratumumabu.
Patients (N = 322) who were treatment naïve or may have received one prior chemotherapy treatment in the metastatic setting [Intent to Treat (ITT) population] were randomised 2:1 to receive trametinib 2 mg once daily or chemotherapy (dacarbazine 1000 mg/m2 every 3 weeks or paclitaxel 175 mg/m2 every 3 weeks).
Bolnike (n = 322), ki še niso bili zdravljeni ali so v okviru metastatske bolezni prejeli eno predhodno kemoterapijo [populacija z-namenom-zdravljenja (ZNZ)], so v razmerju 2:1 randomizirali na prejemanje 2 mg trametiniba enkrat na dan ali kemoterapije (dakarbazin 1000 mg/m2 na 3 tedne ali paklitaksel 175 mg/m2 na 3 tedne).
Patients (n = 391) were randomised 1:1 to receive either IMBRUVICA 420 mg daily until disease progression or unacceptable toxicity, or ofatumumab for up to 12 doses (300/2,000 mg).
Bolnike (n = 391) so randomizirali v razmerju 1:1 tako, da so prejemali bodisi 420 mg zdravila IMBRUVICA dnevno do napredovanja bolezni ali nesprejemljivega toksičnega delovanja zdravila, ali ofatumumab do največ 12 odmerkov (300/2000 mg).
Patients (N = 435) with locally advanced and/or metastatic RCC were randomised to receive pazopanib 800 mg once daily or placebo.
Bolniki (n = 435) z lokalno napredovalim in/ali metastatskim RCC so bili randomizirani tako, da prejemali pazopanib v odmerku 800 mg enkrat na dan ali placebo.